Related Experiment Video
Updated: Dec 18, 2025

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in
Matthias Haase1, Anne Thiel2, Ute I Scholl2,3,4
1Division for Specific Endocrinology, Medical Faculty, University Hospital Duesseldorf, Moorenstr 5, 40225, Düsseldorf, Germany. Matthias.Haase@uni-duesseldorf.de.
Objective:
Fibroblast growth factor receptor (FGFR) 2 regulates the development of the adrenal gland in mice. In addition, FGFR2-mediated signalling has been shown to prevent apoptosis and to enhance proliferation in adrenocortical precursor cells. The activation of the Wingless/Int-1 (WNT)/beta catenin pathway as a key mechanism of adrenocortical tumourigenesis has been linked to FGFR2 signalling in other cell types. Therefore we hypothesised that FGFR2 expression may also play a role in adrenocortical carcinoma (ACC). We conducted a pilot study and analysed protein expression of FGFR2 in 26 ACCs using immunohistochemistry technique. Data on the CTNNB1 mutation status and clinical data were correlated to the expression of FGFR2.
Results:
We observed a high variability in FGFR2 expression between the different tumour samples. There was a subset of ACC with comparatively high nuclear expression of FGFR2. We did not find a clear association between the CTNNB1 mutational status or clinical features and the FGFR2 expression. We conclude that FGFR signalling plays a role in adrenocortical carcinoma. Our data encourages further investigations of FGFR signalling in ACC, especially since new inhibitors of FGFR signalling are already entering clinical trials for the treatment of other cancer types.
Insights
Fibroblast growth factor receptor (FGFR) 2 expression varies in adrenocortical carcinoma (ACC). While not clearly associated with mutations, this suggests FGFR signaling warrants further investigation in ACC treatment.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Fibroblast growth factor receptor (FGFR) 2 regulates adrenal gland development and influences adrenocortical precursor cell proliferation and survival.
- FGFR2 signaling is implicated in the activation of the Wingless/Int-1 (WNT)/beta-catenin pathway, a known mechanism in adrenocortical carcinoma (ACC) development.
Purpose of the Study:
- To investigate the role of FGFR2 expression in human adrenocortical carcinoma (ACC).
- To explore potential correlations between FGFR2 expression, CTNNB1 mutation status, and clinical features in ACC.
Main Methods:
- A pilot study was conducted analyzing FGFR2 protein expression in 26 ACC samples using immunohistochemistry.
- CTNNB1 mutation status and clinical data were collected and correlated with FGFR2 expression levels.
Main Results:
- High variability in FGFR2 expression was observed across different ACC tumor samples.
- A subset of ACCs exhibited notably high nuclear FGFR2 expression.
- No clear association was found between FGFR2 expression and CTNNB1 mutational status or clinical characteristics.
Conclusions:
- FGFR signaling is suggested to play a role in adrenocortical carcinoma.
- Further research into FGFR signaling in ACC is encouraged, particularly given the availability of FGFR inhibitors in clinical trials for other cancers.
Related Concept Videos
Mitogens and the Cell Cycle
Introduction to Fibroblasts
Fibronectins Connect Cells with ECM
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Intracellular Signaling Affects Focal Adhesions
Some...

